[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650291":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":58,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":25,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Gordon Schanzlin New Vision","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BLINK TRIPLE CARE PF","ACTIVE_COMPARATOR","administer Blink Triple care PF QID OU over a period of 30 days",[13],"Drug: Blink tears",{"label":15,"type":16,"description":17,"interventionNames":18},"Systane PRO PF","EXPERIMENTAL","Administer Systane Pro PF QID OU over a period of 30 days",[19],"Drug: Systane PRO",[21,26],{"type":22,"name":23,"description":17,"armGroupLabels":24,"otherNames":25},"DRUG","Systane PRO",[15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Blink tears","Administer Blink Triple Care PF QID OU over a period of 30 days",[9],[31],{"name":32,"affiliation":33,"role":34},"David I Geffen, Doctor Of Optometry","Gordon Schanzlin New Vision Institute","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Rylee Owen","CONTACT","858-455-6800","rowen@gwsvision.com",[42],{"facility":33,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","La Jolla","California","92037","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-117.2742,32.84727,{"lat":53,"lon":52},[56,57],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},{"name":32,"role":34,"phone":25,"phoneExt":25,"email":25},{"type":34,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"David I Geffen, OD,FAAo","Principal Investigator","100650291","phase-4-the-effectiveness-of-systane-pro-preservative-free-verses-blink-triple-care-preservative-free-100650291",false,"NCT07745062","The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free","The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free in Providing Relief From Multiple Symptoms of Dry Eye Disease, and Its Impact on Daily Functioning and Overall Comfort in Dry Eye Subjects","SYSTANEvBLINK","Inclusion Criteria:\n\n* Age: Adults ≥ 18 years.\n* Diagnosis: Clinical diagnosis of mild to moderate dry eye disease in at least one eye with OSDI ≥ 13 to ≤ 32 at screening.\n* OSDI ≥ 13 to ≤ 32 at screening.\n* Objective evidence: NITBUT ≤ 10 seconds in the study eye(s) at screening.\n* Ocular surface status: CFS ≤ grade 3 (Oxford or NEI scale) in the study eye(s).\n* Stable medications: Systemic medications that may affect tear film must be stable ≥ 30 days prior to screening and expected to remain stable during the study.\n* Ability to participate: Able and willing to comply with procedures, attend visits, and provide written informed consent.\n* Contraception: Women of childbearing potential must agree to use an acceptable method of contraception for the study duration and have a negative pregnancy test at screening.\n\nExclusion Criteria:\n\n* Active ocular infection or inflammation unrelated to DED (e.g., bacterial\u002Fviral conjunctivitis, active uveitis).\n* Severe ocular surface disease beyond typical DED (e.g., severe keratitis, Stevens-Johnson syndrome, ocular cicatricial pemphigoid).\n* Excessive corneal staining: CFS \\> grade 3 in the study eye(s).\n* Recent ocular surgery or procedure: ocular surgery, laser, or punctal occlusion within 6 months prior to screening.\n* Current or prior use within 6 months before screening of either study drop (Systane PRO PF or Blink Triple Care PF)\n* Contact lens wear: soft or rigid contact lens use within 7 days prior to baseline, or unwillingness to discontinue lenses for the study; consider extending to 14 days if desired.\n* Use of topical ophthalmic medications that cannot be discontinued (e.g., topical antibiotics, corticosteroids).\n* Recent investigational product use: participation in another interventional trial or investigational product use within 30 days prior to screening.\n* Known hypersensitivity: allergy to any component of Systane PRO PF or Blink Triple Care PF.\n* Confounding systemic conditions: systemic diseases or medications that, in the investigator's judgment, could significantly affect tear production or ocular surface health (e.g., uncontrolled autoimmune disease, recent initiation\u002Fchange of systemic medications known to affect tear production within 30 days).\n* Severe visual impairment in the study eye(s) not attributable to DED that would interfere with assessments.\n* Pregnancy or breastfeeding.\n* Investigator discretion: any medical, psychiatric, or social condition that would preclude safe participation or reliable completion of study procedures.","ALL","18 Years",{"count":72,"type":73},30,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The goal of this investigational study is to determine if Systane PRO Preservative Free is non-inferior to BLINK TRIPLE CARE in the clinically significant improvement of signs and symptoms of dry eye in patients over 4 weeks.",[79],"Dry Eye Disease (DED)",[81],"Dry eye disease","2026-07-29",{"date":84,"type":85},"2026-08-04","ACTUAL",{"date":87,"type":85},"2026-07-17",{"date":89,"type":73},"2027-04-01",{"name":5,"class":6},1]